- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | RENERVE LIMITED: Notice of Annual General Meeting/Proxy Form | - | ASX | ||
| 28.08. | Daily Special: Senetas Corporation, ReNerve, ADX Energy, Castle Minerals, OpenLearning, Patrys | 7 | Finance News Network | ||
| 28.08. | RENERVE LIMITED: ReNerve - Corporate Governance Statement | 1 | ASX | ||
| 28.08. | RENERVE LIMITED: ReNerve - Appendix 4G | 2 | ASX | ||
| 28.08. | RENERVE LIMITED: ReNerve - Full Year Results | 2 | ASX | ||
| 28.08. | RENERVE LIMITED: ReNerve - 2026 Annual Report | 1 | ASX | ||
| 28.08. | RENERVE LIMITED: ReNerve - Appendix 4E | 1 | ASX | ||
| 25.08. | RENERVE LIMITED: Cleansing Notice | - | ASX | ||
| RENERVE Aktie jetzt für 0€ handeln | |||||
| 25.08. | RENERVE LIMITED: Application for quotation of securities - RNV | - | ASX | ||
| 25.08. | RENERVE LIMITED: Proposed issue of securities - RNV | 1 | ASX | ||
| 19.08. | RENERVE LIMITED: Quarterly Investor Presentation | 4 | ASX | ||
| 12.08. | RENERVE LIMITED: Quarterly Investor Webinar | 1 | ASX | ||
| 10.08. | Daily Special: ReNerve, Minerals Exploration, Desert Minerals, D3 Energy, Pure One | 27 | Finance News Network | ||
| 10.08. | RENERVE LIMITED: ReNerve Secures Marketing Approval in India | 1 | ASX | ||
| 06.08. | ReNerve Secures Philippine Marketing Approval for NervAlign Nerve Cuff | 1 | Finance News Network | ||
| 06.08. | RENERVE LIMITED: ReNerve Secures Marketing Approval in the Philippines | 1 | ASX | ||
| 03.08. | RENERVE LIMITED: Change of Director's Interest Notice - J Chick | 2 | ASX | ||
| 29.07. | RENERVE LIMITED: Q4 FY26 Activities Report and Appendix 4C | 1 | ASX | ||
| 23.07. | ReNerve accelerates commercial growth | 2 | Finance News Network | ||
| 13.07. | RENERVE LIMITED: Notification regarding unquoted securities - RNV | - | ASX |
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 43,630 | -1,35 % | AKTIEN IM FOKUS: Zinsanstieg birgt Gefahren für sichere Aktienhäfen | FRANKFURT (dpa-AFX) - Steigende Zinsen an den Kapitalmärkten haben zum Wochenbeginn die Aktienkurse von als sichere Anlagen geltenden Unternehmen belastet. Dazu zählen unter anderen die Immobilienwerte... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 39,220 | +1,61 % | Fresenius Medical Care: Stabilität in stürmischen Zeiten dank robustem Geschäftsmodell | ||
| SIEMENS HEALTHINEERS | 39,000 | +0,49 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen | |
| BILLIONTOONE | 99,50 | 0,00 % | Canaccord initiates BillionToOne stock coverage with buy rating | ||
| CARL ZEISS MEDITEC | 31,560 | -1,87 % | Vom Patent zum Umsatz: Wie Health-Tech-Innovationen den Milliardenmarkt Augengesundheit erreichen - und warum für Rise Nano Optics jetzt die entscheidende Phase beginnt | ||
| HEARTFLOW | 48,880 | 0,00 % | Heartflow, Inc.: Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half | FUSION trial presented at ESC and published in Journal of the American College of Cardiology demonstrates adding non-invasive lesion-specific physiology resolves critical diagnostic uncertainty, supporting... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 13,530 | 0,00 % | Alignment Healthcare Reports Second Quarter 2026 Results, Surpassing High End of Guidance Across All Key Metrics | Generates $1.3 billion in total revenue, representing 31.6% growth year-over-year Grows Medicare Advantage membership 31.5% year-over-year to approximately 294,100 membersRaises the midpoint of all... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 60,75 | +0,03 % | Can BTSG Outgrow the $20B Acute Infusion Market on Volume Growth? | ||
| SANARA MEDTECH | 34,740 | +0,03 % | Sanara MedTech Inc. Reports Second Quarter 2026 Financial Results (Unaudited) | FORT WORTH, TX, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," "Sanara MedTech," the "Company," "we," "our" or "us") (Nasdaq: SMTI), a medical technology company focused on developing... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 22,790 | +0,13 % | PROCEPT BioRobotics Reports First Quarter 2026 Financial Results | SAN JOSE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| BETA BIONICS | 19,410 | -0,05 % | Beta Bionics, Inc.: Beta Bionics Announces Second Quarter 2026 Financial Results and Updates Full Year 2026 Guidance | IRVINE, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial... ► Artikel lesen | |
| AVEANNA HEALTHCARE | 13,580 | 0,00 % | Biotech Stocks At 52-Week Highs - Park Dental Partners +10%, Aveanna Healthcare +24%, Candel Therapeutics +10% on Q2 Reports, Labcorp Holdings, Hemab Therapeutics | LONDON (dpa-AFX) - The following biotech stocks reached 52-week highs on August 13, 2026, driven by key catalysts such as positive quarterly reports and the issuance of increased guidance figures.Park... ► Artikel lesen | |
| LIFESTANCE HEALTH GROUP | 12,730 | 0,00 % | LifeStance Health Group, Inc.: LifeStance Reports Strong Second Quarter 2026 Financial Results and Raises Full Year Outlook | SCOTTSDALE, Ariz., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation's largest providers of outpatient mental healthcare, today announced financial... ► Artikel lesen | |
| PROGYNY | 25,930 | 0,00 % | Progyny stock price target maintained at $31 by Citizens on new offering | ||
| GENEDX | 85,98 | 0,00 % | GeneDx study shows rapid genome sequencing benefits beyond ICUs |
Das Unternehmen RENERVE LIMITED kann der Branche Gesundheitswesen zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RENERVE LIMITED finden Sie auf Wallstreet Online.